Search

Your search keyword '"Aguilar-Company, Juan"' showing total 145 results

Search Constraints

Start Over You searched for: Author "Aguilar-Company, Juan" Remove constraint Author: "Aguilar-Company, Juan"
145 results on '"Aguilar-Company, Juan"'

Search Results

1. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

2. Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

3. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

6. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

7. The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.

8. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

10. Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry

11. An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury.

12. A two-step algorithm avoids corticosteroids in two-thirds of cancer patients with severe immune-mediated hepatitis due to immune checkpoint inhibitors

15. Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

16. Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

17. Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

18. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

20. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries

21. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

23. Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry

24. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

25. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)

26. The FLARE score, circulating neutrophils, and association with COVID-19 outcomes in patients with solid tumors.

27. Machine learning model to predict mortality after discharge in hospitalized oncologic patients (pts) under active systemic therapy in the advanced setting: A multicenter cross-validation study.

28. Clinical effectiveness of SARS-CoV-2 vaccines and booster doses in patients with cancer: An analysis from the European OnCovid registry.

29. Clinical assessment of the Omicron outbreak in Europe and trends in morbidity and mortality from COVID-19 and cancer.

30. Persistence of long-term COVID-19 sequelae in patients with cancer:An analysis from the OnCovid registry

31. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

33. Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study

34. Abstract 701: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

35. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study

36. sj-docx-1-tam-10.1177_17588359211053416 ��� Supplemental material for COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

37. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

38. COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry.

39. Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

40. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

41. Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa

42. WED-263 - A two-step algorithm avoids corticosteroids in two-thirds of cancer patients with severe immune-mediated hepatitis due to immune checkpoint inhibitors

43. Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe

44. Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective

45. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

47. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

48. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe

Catalog

Books, media, physical & digital resources